ES2161702T3 - Procedimiento para la produccion de una vacuna del virus de varicela zoster atenuado. - Google Patents

Procedimiento para la produccion de una vacuna del virus de varicela zoster atenuado.

Info

Publication number
ES2161702T3
ES2161702T3 ES93201521T ES93201521T ES2161702T3 ES 2161702 T3 ES2161702 T3 ES 2161702T3 ES 93201521 T ES93201521 T ES 93201521T ES 93201521 T ES93201521 T ES 93201521T ES 2161702 T3 ES2161702 T3 ES 2161702T3
Authority
ES
Spain
Prior art keywords
production
procedure
vaccine
cells
varicela
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93201521T
Other languages
English (en)
Inventor
Phillip J Provost
David L Krah
Paul A Friedman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/893,295 external-priority patent/US5360736A/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of ES2161702T3 publication Critical patent/ES2161702T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRODUCE UNA VACUNA DEL VIRUS ZOSTER DE VARICELA ATENUADA MEDIANTE PRODUCCION REFORZADA DE VZV. EL NUEVO PROCEDIMIENTO HACE PRODUCCION EN GRAN CANTIDAD DE UNA VACUNA VZV ACTIVA MAS PRACTICA. ADEMAS, CONDICIONES DE CULTIVO DE CELULAS OPTIMIZADAS DE CAPA MONOMOLECULAR PROPORCIONAN UN PROCEDIMIENTO PARA AUMENTAR AL MAXIMO LA DENSIDAD DE LAS CELULAS MONOMOLECULARES, QUE SE USA PARA REFORZAR LA PRODUCCION DE VACUNAS VIRALES. DE CONFORMIDAD CON ESTE PROCEDIMIENTO LAS DENSIDADES DE CELULAS QUE SE ACERCAN A 500.000 CELULAS/CM2 SE OBTIENEN RUTINARIAMENTE EN RECIPIENTES DE CULTIVOS CONVENCIONALES.
ES93201521T 1992-06-04 1993-05-27 Procedimiento para la produccion de una vacuna del virus de varicela zoster atenuado. Expired - Lifetime ES2161702T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89403992A 1992-06-04 1992-06-04
US07/893,295 US5360736A (en) 1992-06-04 1992-06-04 Process for attenuated varicella zoster virus vaccine production

Publications (1)

Publication Number Publication Date
ES2161702T3 true ES2161702T3 (es) 2001-12-16

Family

ID=27129046

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93201521T Expired - Lifetime ES2161702T3 (es) 1992-06-04 1993-05-27 Procedimiento para la produccion de una vacuna del virus de varicela zoster atenuado.
ES01200292T Expired - Lifetime ES2317869T3 (es) 1992-06-04 1993-05-27 Procedimiento de cultivo de celulas en una monocapa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01200292T Expired - Lifetime ES2317869T3 (es) 1992-06-04 1993-05-27 Procedimiento de cultivo de celulas en una monocapa.

Country Status (28)

Country Link
US (1) US5607852A (es)
EP (2) EP0573107B1 (es)
JP (2) JP2599552B2 (es)
KR (1) KR100350169B1 (es)
CN (2) CN1069216C (es)
AT (2) ATE419332T1 (es)
AU (2) AU4392193A (es)
BG (1) BG62176B1 (es)
CA (1) CA2097019C (es)
CZ (2) CZ289574B6 (es)
DE (2) DE69330850T2 (es)
DK (2) DK0573107T3 (es)
ES (2) ES2161702T3 (es)
FI (1) FI117758B (es)
GR (1) GR3036812T3 (es)
HU (1) HU220080B (es)
MX (1) MX9303274A (es)
NO (1) NO314068B1 (es)
NZ (1) NZ253527A (es)
PT (2) PT573107E (es)
RO (1) RO114906B1 (es)
RS (1) RS50330B (es)
RU (1) RU2126269C1 (es)
SK (1) SK279387B6 (es)
TW (1) TW349868B (es)
UA (1) UA27137C2 (es)
WO (1) WO1993024616A1 (es)
YU (1) YU49210B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995029991A1 (en) 1994-04-28 1995-11-09 Aviron A novel vzv gene, mutant vzv and immunogenic compositions
KR0177323B1 (ko) * 1996-02-16 1999-04-01 성재갑 바이러스 백신 생산에 유용한 사람 이배체 폐세포 및 이를 이용한 수두 백신의 제조방법
EP1983044B1 (en) * 1996-10-10 2016-08-10 Life Technologies Corporation Animal cell culture media comprising plant-derived nutrients
US20040171152A1 (en) * 1996-10-10 2004-09-02 Invitrogen Corporation Animal cell culture media comprising non-animal or plant-derived nutrients
GB9716611D0 (en) * 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
KR100378909B1 (ko) * 1998-03-18 2003-12-18 주식회사 엘지생명과학 사람세포주를이용한풍진백신의생산수율증대방법
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
WO1999057246A1 (en) * 1998-05-01 1999-11-11 Life Technologies, Inc. Animal cell culture media comprising non-animal or plant-derived nutrients
US20060286668A1 (en) * 1999-04-30 2006-12-21 Invitrogen Corporation Animal-cell culture media comprising non-animal or plant-derived nutrients
JP3946045B2 (ja) * 2000-01-31 2007-07-18 財団法人阪大微生物病研究会 弱毒生水痘ワクチンの品質管理方法
CN1318580C (zh) * 2003-07-10 2007-05-30 北京科兴生物制品有限公司 可满足灭活疫苗生产的sars病毒规模化制备及灭活的方法
RU2259214C1 (ru) * 2004-01-28 2005-08-27 Федеральное государственное унитарное предприятие "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" Министерства здравоохранения Российской Федерации Способ получения вакцины оспенной инактивированной сухой "оспавир"
US7344839B2 (en) * 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
CN101578362A (zh) * 2006-10-17 2009-11-11 米迪缪尼有限公司 影响病毒脂质的成分
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
EP2310495B1 (en) * 2008-08-11 2017-11-22 Sanofi Pasteur Biologics, LLC Compositions and methods for the production of alpha-herpesvirus 2
CN101967466A (zh) 2009-07-28 2011-02-09 新泽西医学院 Orf7缺陷型水痘病毒株、含有该毒株的疫苗及其应用
FR2952825B1 (fr) 2009-11-24 2012-05-25 Goaster Jacqueline Le Utilisation d'un vaccin contre le virus vzv/hsv3 pour traiter les infections herpetiques par le virus hsv1 et/ou le virus hsv2
CN101972474B (zh) * 2010-11-11 2012-06-27 长春祈健生物制品有限公司 冻干带状疱疹减毒活疫苗及制备方法
JP2014508522A (ja) * 2011-02-24 2014-04-10 モガム バイオテクノロジー リサーチ インスティチュート 新規な水痘帯状疱疹ウイルス株及びそれを用いた水痘及び帯状疱疹ウイルスワクチン
WO2014062060A1 (en) * 2012-10-18 2014-04-24 Erasmus University Medical Center Rotterdam New method for producing high titer cell-free vzv vaccine virus
CN103074304B (zh) * 2013-01-28 2016-01-13 江苏健安生物科技有限公司 高水平人二倍体细胞培养水痘-带状疱疹疫苗病毒方法
WO2015034807A2 (en) * 2013-09-05 2015-03-12 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
CN103740735B (zh) * 2013-12-31 2016-04-06 李越希 化学合成的HSV2病毒gC糖蛋白胞外区基因片段及其表达、应用
DK3226894T3 (da) * 2014-12-01 2019-10-21 Transgene Sa Stabile flydende vacciniavirus-formuleringer
RU2637093C1 (ru) * 2016-12-20 2017-11-29 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы
CN107174658B (zh) * 2017-04-29 2020-11-27 安徽智飞龙科马生物制药有限公司 人用水痘病毒灭活疫苗及其制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660565A (en) * 1968-04-17 1972-05-02 Wistar Inst Rubella vaccine and method
US3555149A (en) * 1968-07-05 1971-01-12 Merck & Co Inc Mumps vaccine and its preparation
US3919411A (en) * 1972-01-31 1975-11-11 Bayvet Corp Injectable adjuvant and compositions including such adjuvant
US3915794A (en) * 1973-02-09 1975-10-28 Rit Rech Ind Therapeut Stabilizing compositions for cell-free viruses and cell-free virus preparations containing them
JPS5341202B2 (es) * 1974-03-12 1978-11-01
US3961046A (en) * 1974-12-02 1976-06-01 American Cyanamid Company Mumps vaccine and preparation thereof
US4000256A (en) * 1975-04-30 1976-12-28 Merck & Co., Inc. Varicella vaccine and process for its preparation
GB1481650A (en) * 1975-05-06 1977-08-03 Merck & Co Inc Chemical processes and products
JPS5251009A (en) * 1975-10-17 1977-04-23 Morinaga Milk Ind Co Ltd Method of producing drug for treating marrow leukemia
US4147772A (en) * 1976-02-03 1979-04-03 Merck & Co., Inc. Vaccine stabilizer
JPS5341202A (en) * 1976-09-28 1978-04-14 Fuji Photo Film Co Ltd Novel magnetic recording medium
JPS55147227A (en) * 1979-05-04 1980-11-17 Handai Biseibutsubiyou Kenkyukai Preparrtion of attenuated live mumps vaccine
US4252792A (en) * 1979-09-21 1981-02-24 Douglas Industries, Inc. Injectable rabies vaccine composition and method for preparing same
US4273762A (en) * 1979-12-03 1981-06-16 Merck & Co., Inc. Lyophilization process for live viral compositions
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4337242A (en) * 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
US4772466A (en) * 1983-08-22 1988-09-20 Syntex (U.S.A.) Inc. Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
JPS624370A (ja) * 1985-07-01 1987-01-10 Sharp Corp 半導体素子
US5024836A (en) * 1987-05-04 1991-06-18 Merck & Co., Inc. Stable lyophilized live herpes virus vaccine
AU4312489A (en) * 1988-09-23 1990-04-18 Cetus Corporation Lipid microemulsions for culture media
US5360736A (en) * 1992-06-04 1994-11-01 Merck & Co., Inc. Process for attenuated varicella zoster virus vaccine production

Also Published As

Publication number Publication date
GR3036812T3 (en) 2002-01-31
ATE206311T1 (de) 2001-10-15
EP1097988A1 (en) 2001-05-09
PT573107E (pt) 2002-02-28
BG99227A (bg) 1995-07-28
JPH09107958A (ja) 1997-04-28
NO944654D0 (no) 1994-12-02
CA2097019C (en) 2007-07-24
CZ289574B6 (cs) 2002-02-13
PT1097988E (pt) 2009-03-05
HUT71863A (en) 1996-02-28
JPH06172215A (ja) 1994-06-21
AU4003693A (en) 1993-12-09
MX9303274A (es) 1994-01-31
KR100350169B1 (ko) 2004-05-20
CN1069216C (zh) 2001-08-08
RU2126269C1 (ru) 1999-02-20
FI945697A0 (fi) 1994-12-02
EP0573107B1 (en) 2001-10-04
RS50330B (sr) 2009-11-10
YU7504A (sh) 2006-08-17
CZ304594A3 (en) 1995-10-18
YU38893A (sh) 1996-02-19
EP0573107A2 (en) 1993-12-08
JP2599552B2 (ja) 1997-04-09
HU9403473D0 (en) 1995-02-28
RO114906B1 (ro) 1999-08-30
EP1097988B1 (en) 2008-12-31
FI117758B (fi) 2007-02-15
DK0573107T3 (da) 2001-11-12
EP0573107A3 (en) 1995-04-26
DE69330850T2 (de) 2002-04-11
JP3156962B2 (ja) 2001-04-16
DK1097988T3 (da) 2009-05-04
CN1307902A (zh) 2001-08-15
YU49210B (sh) 2004-09-03
AU4392193A (en) 1993-12-30
TW349868B (en) 1999-01-11
NO314068B1 (no) 2003-01-27
UA27137C2 (uk) 2000-02-28
WO1993024616A1 (en) 1993-12-09
DE69330850D1 (de) 2001-11-08
FI945697L (fi) 1995-01-26
HU220080B (hu) 2001-10-28
NO944654L (no) 1995-02-03
US5607852A (en) 1997-03-04
NZ253527A (en) 1996-09-25
AU673167B2 (en) 1996-10-31
CN1082923A (zh) 1994-03-02
SK279387B6 (sk) 1998-10-07
DE69334254D1 (de) 2009-02-12
BG62176B1 (bg) 1999-04-30
ATE419332T1 (de) 2009-01-15
SK148094A3 (en) 1995-07-11
CA2097019A1 (en) 1993-12-05
ES2317869T3 (es) 2009-05-01
CZ289690B6 (cs) 2002-03-13

Similar Documents

Publication Publication Date Title
ES2161702T3 (es) Procedimiento para la produccion de una vacuna del virus de varicela zoster atenuado.
ES2131503T3 (es) Procedimiento para la preparacion de acidos 2-aril-propionicos.
UY24668A1 (es) Metodo para producir lineas de celulas inmortalizadas para crecimiento de virus
ES9000011A1 (es) Procedimiento para transformar un cultivo de celulas de modo que produzca activador de plasminogeno de tejido (t-pa) humano
ATE192653T1 (de) Anwendungen von acemannan
ES2194833T3 (es) Nuevas entidades para la terapia del cancer.
PT1077072E (pt) Processo in vitro para produzir uma protese homologa de valvula cardiaca ou uma protese homologa de vaso sanguineo
ES2145047T3 (es) Generacion in vitro de celulas dendriticas humanas.
ES2171752T3 (es) Procedimiento para la obtencion de proteinas recombinantes en e. coli por medio de fermentacion en alta densidad celular.
ES2090297T3 (es) Produccion de proteinas que utilizan recombinacion homologa.
ES2038689T3 (es) Procedimiento de cultivo del virus de la rinotraqueitis infecciosa de la pava, y vacuna preparada a partir del virus asi obtenido.
ES2060803T3 (es) Soporte biologico para cultivos celulares constituido por proteinas plasmaticas coaguladas por trombina, su utilizacion para el cultivo de los queratinocitos, su recuperacion y su transporte con fines de utilizacion terapeutica.
ES504199A0 (es) Un metodo para aumentar el rendimiento de vha en un cultivo celular in vitro
ATE170557T1 (de) Züchtung von insektenzellen mit airlift-reaktoren
ES8600938A1 (es) Un procedimiento para preparar el antigeno de superficie de la hepatitis b
ES8202357A1 (es) Un procedimiento para preparar una vacuna de virus de la ra-bia inactivados
RU93052287A (ru) Способ ускоренного получения биокомпоста на основе птичьего помета
AU6949994A (en) Animal model for hepatitis virus infection
ATE10806T1 (de) Verfahren zur herstellung von hepatitis boberfl[chenantigen.
ES8701837A1 (es) Procedimiento para producir una composicion viral ateunada viva uniforme de hepatitis a.
ES2065915T3 (es) Procedimiento para aumentar la expresion de polipeptidos en un cultivo de celula recombinante.
ES2191064T3 (es) Procedimiento para producir proteinas.
AU571488B2 (en) Semiconductor laser
BRPI0418641A (pt) organização similar a tecido de células e construtos similares a tecidos macroscópicos, gerados por cultura de macromassa de células, e método de cultura de macromassa
CN1336622A (zh) 立体沙盘模型制作方法

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 573107

Country of ref document: ES